Researchers from the UCLA Health Jonsson Comprehensive Cancer Center and The University of Texas MD Anderson Cancer Center ...

LUT014 works by paradoxically reactivating MAPK, a key signaling pathway in the skin that anti-EGFR therapies shut down.

A new topical gel called LUT014 successfully reduced the severity of a painful acne‐like rash that commonly occurs as a side effect of targeted therapy with epidermal growth factor receptor (EGFR) ...

However, like other EGFR-targeted therapies ... Standard-of-care dermatologic management included general skin prophylaxis per local practice and reactive treatment, such as topical steroids ...

A panelist discusses how the COCOON study demonstrated that enhanced dermatologic management significantly reduces the ...

Overall, rates of several adverse events related to EGFR or MET inhibition were notably higher in the Rybrevant-Lazcluze arm. Grade 3 or above paronychia—an inflammation of the skin around the ...

During a live event, Xiuning Le, MD, PhD, discussed updated intracranial efficacy, overall survival, and safety of ...

The randomized, open-label, multicenter COCOON study evaluated the efficacy of the combination therapy in reducing the incidence of skin and nail adverse events (AEs) commonly associated with ...

A total of 337 treatment-naïve patients with EGFR-sensitive mutation-positive locally advanced or metastatic NSCLC were enrolled and randomized 1:1 to receive either limertinib or gefitinib.